Neuroscience Antibodies and Assays Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast 2024-2028

Neuroscience Antibodies and Assays Market 2024-2028

The global neuroscience antibodies and assays market size is estimated to grow by USD 2.20 billion at a CAGR of 9.64% between 2023 and 2028. 

Recombinant-based engineering is one of the major technological advances in antibody manufacturing techniques. The manufacturing process of recombinant antibodies is chemically defined, giving high purity and ultralow batch-to-batch variability. In comparison with conventional antibodies, recombinant antibodies have several advantages, such as improved tissue penetration, broader biodistribution, and smaller size. Further, automated immunoassay systems have significantly helped to reduce time, labor, and human errors and improve the efficiency of the immunoassay workflow by automating several key steps, such as wash steps, detection and data management, reagent additions, and incubations. Technological advances in microplate readers are increasing the speed and sensitivity of assays and reducing the risk of wasting expensive reagents, samples, and time. Therefore, technological advances in antibody manufacturing will enhance the growth of the neuroscience antibodies and assays market during the forecast period.

Technavio has segmented the market into Type, Application , and Geography 

• The type segment is classified into consumables and instruments
• The application segment is classified into pharmaceutical and biopharmaceutical companies, academic and research institutes, and hospital and diagnostic centers
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Neuroscience Antibodies and Assays Market During the Forecast Period?

To learn more about this report, Request Free Sample

Neuroscience Antibodies and Assays Market Segmentation by Type, Application and Geography Analysis

Type Analysis

Consumables

The market share growth by the consumables segment will be significant during the forecast period. A wide range of antibodies, assay kits, and reagents are used in neuroscience assays to discover new disease targets, provide high-throughput screening of clinical compounds, understand the mechanism of action, and develop clinically relevant biomarkers.

Get a glance at the market contribution of various segments Download PDF Sample

The consumables segment was the largest and was valued at USD 1.86 billion in 2018. The demand for neuroscience antibodies, antigens, assay kits, and reagents has significantly increased due to the discovery of new potential drug targets, signaling molecules, and structural proteins in the brain. Furthermore, the growing significance of neuroscience processes and neuronal diseases research, and the wide availability of antibodies, assay kits, and reagents will drive the growth of the consumables segment and propel the global neuroscience antibodies and assays market during the forecast period.

Application Analysis

Pharmaceutical and biopharmaceutical companies 

Pharmaceutical and biopharmaceutical companies use neuroscience antibodies to identify and validate potential drug targets associated with neurological disorders. This involves characterizing the expression and function of specific proteins implicated in diseases such as Alzheimer's, Parkinson's, and neurodegenerative conditions.  Companies develop companion diagnostics using neuroscience antibodies to identify patient subpopulations that are more likely to respond to a particular therapeutic intervention. This personalized medicine approach can improve treatment outcomes and reduce the risk of adverse effects. Thus, neuroscience antibodies and assays are indispensable tools in pharmaceutical and biopharmaceutical companies for advancing the understanding of the nervous system, identifying potential drug targets, and facilitating the development of novel therapeutic interventions for neurological disorders. Hence, factors such as target identification and validation, neurotoxicity assessment, and preclinical drug development will boost the growth of the pharmaceutical and biopharmaceutical companies segment and impel the market during the forecast period.

Academic and research institutes

Academic institutes include end-users such as universities and drug research institutes. The segment includes the use of fluidic technology for research purposes, such as microfluidics research, neuroscience research, cellular research, and other life science experiments involving chromatography and mass spectrometry. Further, the research operations are sponsored by key players or government entities, which, in turn, will help them to enhance R&D activities. For instance, after decades of R&D on the biomarkers in Alzheimer's disease, biomarkers have a significant impact on the development of disease-modifying therapies. Therefore, the R&D on neuroscience antibodies and assays are expected to drive the growth of the academic and research institutes segment and boost the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The neuroscience antibodies and assays market in North America is expected to increase during the forecast period. North America, particularly the US and Canada, boasts world-class research institutions, universities, and medical centers. The region has a growing prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and neuropsychiatric conditions. The rising incidence of these disorders drives the need for research tools, diagnostics, and potential therapeutic interventions. The increasing demand for the diagnosis of neurological disorders has boosted the demand for neuroscience antibodies and assays. For instance, there is a growing societal awareness of mental health issues in North America. This awareness drives research into the neurological basis of mental health conditions and increases the demand for tools for biomarker discovery and diagnostic development.

For instance, according to the National Institutes of Health, Alzheimer's disease affects an estimated 6.5 million Americans aged 65 and up now. This figure could rise to 13.8 million by 2060 if no medical breakthroughs are made to prevent, halt, or cure Alzheimer's disease. Thus, the high prevalence of neurological disorders, the growing aging population, high healthcare expenditure on treating neurological diseases, and favorable reimbursement policies for neuro-diagnostic procedures are expected to drive the growth of the regional market during the forecast period.

Buy the Full Report Now

Key Neuroscience Antibodies and Assays Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abcam plc  - The company offers neuroscience antibodies and assays that include anti Ki67 antibodies, anti-vimentin antibodies, anti-beta catenin antibodies, and anti-BrdU antibodies.

• Abnova Corp.
• ADx NeuroSciences NV
• Bio Rad Laboratories Inc.
• Biosensis Pty Ltd.
• BMG LABTECH GmbH
• Cell Signaling Technology Inc.
• Chemie Brunschwig AG
• Elabscience Biotechnology Inc.
• Enzo Biochem Inc.
• F. Hoffmann La Roche Ltd.
• GenScript Biotech Corp.
• Kaneka Corp.
• Merck and Co. Inc.
• NSJ Bioreagents
• PerkinElmer Inc.
• Proteintech Group Inc.
• Rockland Immunochemicals Inc.
• Santa Cruz Biotechnology Inc.
• Siemens AG

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Neuroscience Antibodies and Assays Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Neuroscience Antibodies and Assays Market Drivers

Increasing initiatives and support from governments and healthcare organizations are notably driving the market growth. Governments and healthcare organizations are taking various initiatives to improve access to healthcare for patients with neurological disorders. For instance, the World Health Organization (WHO) is working with its partners and stakeholders to improve access to care for individuals with epilepsy. Furthermore, the National Institute of Neurological Disorders and Stroke (NINDS), a component of NIH, aims to reduce the burden of neurological diseases through research and by improving treatments and preventive measures.

Similarly, Brain Awareness Week, organized by the Dana Alliance for Brain Initiative, is a global campaign that aims to advance public awareness about the progress and benefits of brain research. However, public spending on neurological diseases has also increased, which, in turn, is expected to promote the growth of the market during the forecast period.

Significant Neuroscience Antibodies and Assays Market Trends

Increasing clinical trials is an emerging trend shaping the market growth. The globalization of clinical trials has consistently expanded over the past two decades, which has been credited to numerous components, including organized trials, voluntary members, accessibility of qualified local investigators, improved infrastructure facilities, and the low expense of clinical trials in developing nations. The potential clinical advantages for disease-specific biomarkers incorporate faster and more accurate disease analysis and potential diminishing in sample size and time of clinical trials, which will accelerate drug development. The use of biomarkers in the clinical field of neurological disorders is expected to figure out whether a medication achieves its proposed target or changes the course of the disease.

Moreover, both the US FDA and the European Medicines Agency (EMA) perceive the role of biomarkers in the medication improvement process, which has led to the formation of an ethical committee between the developed and emerging countries to provide standard, effective, and consistent ethical guidance. This avoids the exploitation of participants in clinical trials with the help of the US FDA monitoring for low-cost and effective clinical trials in developing countries. Thus, the increase in clinical trials will drive the growth of the market during the forecast period.

Major Neuroscience Antibodies and Assays Market Challenges

The high development cost of neuroscience antibodies is a significant challenge hindering the market growth during the forecast period. The development cost of neuroscience antibodies is significantly high. Unlike therapeutic antibodies, which can generate billions of USD in revenue, research antibodies sometimes do not even compensate for their development costs, which are in the range of only thousands of USD. Development costs are significantly different depending on the type of antibody generated. Several companies find it challenging to generate significant annual sales for their research antibodies. Several monoclonal antibodies do not reach the break-even point for a research application. Hence, most commercial research antibodies are still polyclonal ones, which cost significantly less in development.

Furthermore, due to the high development cost, manufacturers of neuroscience antibodies forego exhaustive in-depth quality control of the research antibodies. Such products can lead to unfounded conclusions, waste of research efforts, and faulty research publications that need to be retracted, which will impede the growth of the market during the forecast period.

Buy Now Full Report

Key Neuroscience Antibodies and Assays Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Neuroscience Antibodies and Assays Market Customer Landscape

Segment Overview

The neuroscience antibodies and assays market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Type Outlook
  • Consumables
  • Instruments

• Application Outlook
  • Pharmaceutical and biopharmaceutical companies
  • Academic and research institutes
  • Hospital and diagnostic centers

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest Of World
    • Brazil
    • Argentina 
    • Australia 

Neuroscience Antibodies and Assays Market Scope
Report Coverage	Details
Page number	162
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 9.64%
Market Growth 2024-2028	USD 2.20 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	9.13
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 46%
Key countries	US, Germany, UK, France, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abcam plc, Abnova Corp., Bio Rad Laboratories Inc., Biosensis Pty Ltd., BMG LABTECH GmbH, Cell Signaling Technology Inc., Chemie Brunschwig AG, Elabscience Biotechnology Inc., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, NSJ Bioreagents, PerkinElmer Inc., Proteintech Group Inc., Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download the Sample PDF at your Fingertips

What are the Key Data Covered in this Neuroscience Antibodies and Assays Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the neuroscience antibodies and assays market between 2024 and 2028
• Precise estimation of the neuroscience antibodies and assays market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of neuroscience antibodies and assays market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch